Kornimate/medical-research-clean huggingface dataset:
comparison of respiratory muscle, pain, functional performance and cognitive status in obstructive lung diseases

Conditions: Pain, Chronic; Obstructive Pulmonary Disease; Cognitive Impairment; Functional Disturbance

Summary: in the literature, there are a limited number of studies evaluating postural awareness, cognitive status, respiratory muscle strength and endurance, functional capacity, and pain in people with obstructive pulmonary disease, and comparing these parameters with each other and with healthy subjects, and most of the studies are on chronic obstructive pulmonary disease patients. there we will evaluate these parameters in different obstructive lung diseases and compare the findings of healthy individuals.


Eligibility criteria:
inclusion criteria for obstructive lung diseases 1. to be diagnosed with obstructive pulmonary disease, 2. have not experienced acute exacerbation in the last 3 months, 3. being between the ages of 18-65, 4. not having chronic pain problems, 5. volunteer for research, 6. to be able to walk and cooperate. exclusion criteria for obstructive lung diseases 1. to be able to diagnose neurological disorder, 2. to have an advanced orthopedic disease that may affect functional capacity measurement. criteria for non-inclusion for healthy group 1. to have any cardiopulmonary disease, 2. to have an advanced orthopedic disease that may affect functional capacity measurement.
satisfaction survey on pins stimulator system for patients with parkinson's disease

Conditions: Parkinson's Disease

Summary: this study will be done because the investigators would like to evaluate product satisfaction of two pins products (product a, product b) that are to evaluate the effectiveness of rechargeable and non-rechargeable deep brain stimulation (at baseline visit and at follow-up visit) and by evaluating their responses to the product satisfaction survey that will be given to them by a study coordinator.

other: ipgs products patients implanted with the rechargeable ipgs and non-rechargeable were followed before and 3 months after dbs surgery and completed a systematic survey of satisfaction with pins stimulator system.

Eligibility criteria:
inclusion criteria: 1. subject is 18 to 80 years of age. 2. subject has been diagnosed, by a neurologist, with idiopathic parkinson's disease. 3. the pd patients can recharge the neurostimulator independently, with favourable compliance and commit to cooperate with the clinical trial study, 4. subjects are pins neurostimulator users exclusion criteria: subject were major depression with suicidal thoughts (a score of \>25 on the beck depression inventory ii,20 with scoresranging from 0 to 63 and higher scores indicating worse functioning), tumor, abnormality in routine liver and renal function, cerebral infarction, hydrocephalus, encephalatrophy, stroke sequela, heart disease, thrombocytopenia, hyperthermalgesia and any medical or psychological problem that would interfere with the conduction of the study protocol.patients with symptoms of the midline at the state of off medication such as severe language barrier, dysphagia, disequilibrium, slipping-clutch gaitwere excluded. patients who had undergone other implantation such as cardiac pacemaker, artificial cochlea because of the accompanied diseases such as were excluded. patients with history of pallidotomy, stereotactic radiofrequency (gamma knife) and cell transplantation were also excluded.

Keywords: parkinson's disease, deep brain stimulation
non-insulino-dependant diabetes in infants and teenagers

Conditions: Diabetes; Pediatric Disorder

Summary: the incidence of diabetes in children, which is constantly increasing worldwide is estimated in mainland france at about 15/100 000 per year with a wide disparity between countries and a north gradient south. in reunion island, about 30 children a year seem to reveal diabetes before the age of 18 years but no precise data has ever been published on this subject. indeed, while type 1 diabetes (insulin-dependent autoimmune) represents historically the majority of cases of diabetes revealed at pediatric age (about 90%), since a little more than 10 years other types of diabetes seem emerge at pediatric age. this is particularly the case of type 2 diabetes in connection with the global epidemic of obesity. the purpose of the investigator's study is the exhaustive prospective collection of all cases of diabetes revealed before the age of 18 in the reunion region over a period of 5 years.


Eligibility criteria:
inclusion criteria: * child or adolescent residing in the territory of the reunion island * with a diagnosis that revealed diabetes according to criteria defined by who (world health organization) before 18 years of age * parents who signed the participation consent exclusion criteria: * patient not residing in the usual way in reunion island
ida+bucy vs bucy conditioning regimen for intermediate-risk aml undergoing auto-hsct

Conditions: Autologous Hematopoietic Stem Cell Transplantation; Acute Myeloid Leukemia; Conditioning

Summary: autologous hematopoietic stem cell transplantation (auto-hsct) is an effective alternative to allogeneic hsct for intermediate-risk acute myeloid leukemia (aml) without hla-matched donors. at present, the best conditioning regimen for aml undergoing auto-hsct remains in discussion. in this study, the safety and efficacy of ida+bucy and bucy myeloablative conditioning regimens in intermediate-risk aml undergoing auto-hsct are evaluated.

auto-hsct is an effective alternative to allogeneic hsct for intermediate-risk aml without hla-matched donors. bucy conditioning regimen is the standard myeloablative regimen. however, auto-hsct with bucy conditioning regimen appears to have higher relapse rate. to reduce the relapse rate, ida is added in the conditioning regimen. in this study, the safety and efficacy of ida+bucy and bucy myeloablative conditioning regimens in intermediate-risk aml patients undergoing auto-hsct are evaluated.

Eligibility criteria:
inclusion criteria: * intermediate-risk aml * achieving cr after one cycle induction,then receiving three cycles of consolidation therapy including moderate and high doses of ara-c combined regimens * with negative mrd before mobilization and collect of peripheral blood stem cells * without hla-matched donors (related and unrelated) * refusal of haploidentical hematopoietic stem cell transplantation exclusion criteria: * any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * patients with any conditions not suitable for the trial (investigators' decision)
reliability of artificial intelligence for treatment decision for adult skeletal open bite patients

Conditions: Openbite; Artifical Intelligence

Summary: this study evaluated a specially designed ai model developed by a programmer using x-ray readings and corresponding treatment decisions from 70% of the cases (either orthodontic treatment only or orthodontic treatment with surgery). for the evaluation, we will use the remaining 30% of cases. "subsequently, to assess its performance, the model was tested on the remaining 30% of cases. the programmer provided only the x-ray readings as input. the ai model was then tasked with classifying.

in this study, all patients were treated completely with a well-finished result by expert orthodontists. this study evaluates whether an artificial intelligence (ai) model can enhance treatment decisions for adult skeletal open bite cases by predicting the optimal intervention, either orthognathic surgery or camouflage, using cephalometric readings as input data. first, a total of 53 cases were analyzed, which were divided into two groups: 70% were allocated to the machine learning group (mlg), while the remaining 30% constituted the test group (tg). cephalometric analysis for all patients was performed using dolphin imaging 11.5 premium software, along with determining the appropriate treatment decision, either camouflage or orthognathic surgery. the data obtained from mlg serves as training data for the ai model to classify cases based on their cephalometric data, whether for camouflage or orthognathic surgery. the input data consisted of cephalometric readings along with a decision. second, after machine learning, validation takes place to examine the ability of the machine to make decisions through some cases from mlg. the third step will evaluate the machine's ability to accurately determine case decisions based on cephalometric readings. the results produced by the machine will be compared to the actual decisions made, as all these cases were treated under the supervision of orthodontic professors.

Eligibility criteria:
inclusion criteria: * moderate to severe adult patients with anterior skeletal open bite (at least 3mm opening) * completed their treatment successfully. * well-documented cases with comprehensive preoperative and postoperative lateral cephalometric x-rays were considered. exclusion criteria: * patient below 18 years. * improperly finished orthodontic treatment. * incomplete documentation. * cleft lip and palate patient, patient with syndromes. * dental open bite.
mother's recorded voice versus dexmedetomidine on postoperative agitation

Conditions: Agitation, Emergence

Summary: the aim of this study is to compare the efficacy of mother's recorded voice versus dexmedetomidine injection on postoperative agitation in children undergoing elective surgery.

a written informed consent will be taken from the patients' legal guardians.patients will be assigned randomly to three groups (30 subjects each) to be anesthetized and either randomly assigned to listen to the mother's recorded voice at 2 times (in the holding area 3 minutes before induction of anesthesia till induction of anesthesia is ended) and (during emergence from anesthesia till complete recovery) (group m) or will be given a single bolus of dexmedetomidine 0.2 µ/kg iv at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery) (group d) or given the same volume of saline iv at 2 times (in the holding area 3 minutes before induction of anesthesia) and (at the end of surgery) (group c).to keep blinding, group m will be injected iv with the same volume of saline at the same 2 times as in groups d \& c while in groups d \& c, headphones will be putted as in group m at the same 2 times with no recorded voice.

Eligibility criteria:
inclusion criteria: * children (age 4-9 years) * american society of anesthesiologists physical status (asa) i-ii who will be listed for outpatient elective surgery under general anesthesia. exclusion criteria: * developmental delays * neurological diseases * deafness * hearing impairment * maternal mutism * absence of the mother
effect of increased fruit and vegetable intake on chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is the uk's fastest growing fatal disease and is estimated to cost the health service close to £1 billion every year. around 80,000 people in northern ireland suffer from copd. copd is clinically defined as a slowly progressive condition characterised by airflow limitation, which is largely irreversible. chronic inflammation and oxidative stress are key components of the underlying pathological process resulting in airflow limitation. dietary factors and nutrients that have antioxidant or anti-inflammatory properties are therefore of interest with respect to the aetiology of copd. the antioxidant vitamins c, e and beta-carotene are all present in the lung milieu. such antioxidants represent the lung's first line of defence against oxygen free radicals. observational studies indicate that a low dietary intake of antioxidant nutrients, or foods rich in antioxidants (e.g. fruit and vegetables), is associated with decreased lung function and increased risk of copd. to date, there have been no food-based dietary interventions investigating the effect of increased fruit and vegetable intake on copd. the investigators propose to recruit people with mild to moderate copd and low fruit and vegetable intakes (\<=2 portions daily) and randomise them to one of two study arms for 12 weeks - either to increase fruit and vegetable consumption to at least 5 portions a day, or to follow their normal diet. airway and systemic oxidative stress and inflammation will be assessed at baseline and post-intervention in order to determine if fruit and vegetables have the potential to alleviate the oxidative stress and airway inflammation associated with copd.


Eligibility criteria:
inclusion criteria: * moderate to severe copd (according to gold classification) * oxygen saturation \>= 92 kpa * symptomatically stable * habitually low fruit and vegetable intakes (\<=2 portions daily) * exercise limited by shortness of breath (rather than e.g. angina, arthritis) exclusion criteria: * diabetes * taking antioxidant supplements or drugs * oxygen saturation \<8kpa

Keywords: copd fruit vegetables oxidative stress inflammation
open-label, long-term treatment study, to assess the long-term safety and tolerability and efficacy of neramexane in patients with subjective tinnitus

Conditions: Subjective Tinnitus

Summary: the purpose of this study is to investigate the long-term safety and tolerability and efficacy of neramexane mesylate in the long-term treatment of subjective tinnitus after a completed double-blind randomized placebo controlled study


Eligibility criteria:
main inclusion criteria: * male or female patients who have successfully completed one of the double-blind phase 3 tinnitus studies of merz with neramexane mesylate * patients aged equal or older 18 but not older than 75 years with clinical diagnosis of first onset, persistent (i.e. tinnitus should never be absent for more than 24 hours in a row), subjective, uni-or bilateral subacute tinnitus at the timepoint of the lead-in study main exclusion criteria: * clinical diagnosis of intermittent or pulsatile tinnitus * patients who have tinnitus as a concomitant symptom of an otological/neurological disease (such as otitis media, meniére´s disease, otosclerosis etc.)
transient elastography in the determination of advanced fibrosis in alcoholic liver disease.

Conditions: Alcoholism; Liver Disease; Liver Fibrosis

Summary: alcoholic liver disease is the most frequent complication of excessive alcohol consumption. early diagnosis of alcoholic liver disease is essential to avoid its complications that could be fatal. to date, the reference diagnostic tool is an invasive procedure: the liver biopsy. the transient elastography is a useful tool for early diagnosis of liver fibrosis. this tool is validated in the diagnosis of liver fibrosis due to c chronic hepatitis. because it is non-invasive, fast, given immediate results; transient elastography could be repeated in alcoholic patients for liver fibrosis follow-up. in the present study, the investigators propose to realize liver biopsy and transient elastography in 300 alcoholic patients in weaning to evaluate the transient elastography accuracy in the exclusion of sever liver fibrosis (metavir 3 and 4). the reference liver fibrosis diagnosis tool will be the liver biopsy.


Eligibility criteria:
inclusion criteria: * patients more than 18 years old; hospitalised for alcoholic weaning; with an alcoholic liver disease; with at risk alcoholic consumption; with an indication of liver biopsy; with a signed consentment. exclusion criteria: * patients with a cirrhosis; with other causes of liver disease; with a contraindication of liver biopsy; having had a liver biopsy in the last 3 years; pregnancy; major benefiting from a legal protective measure; no coverage care.

Keywords: transient elastography alcoholic liver disease liver fibrosis
dose-finding trial of hcd122 in patients with chronic lymphocytic leukemia (cll) that is relapsed or non-responsive to prior fludaribine therapy

Conditions: Chronic Lymphocytic Leukemia

Summary: the purpose of this study is to determine the highest tolerated dose, safety and activity of hcd122 in patients with chronic lymphocytic leukemia who are relapsed after receiving prior treatment.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of cll requiring treatment * refractory or relapsed disease * prior treatment with fludarabine * male or female * \>18 years of age exclusion criteria: * treatment with rituximab within 90 days and alemtuzumab or any monoclonal antibody within 6 months. * clinically significant cardiac dysfunction or other significant organ dysfunction additional eligibility criteria apply that will be reviewed with potential study subjects at the site.

Keywords: lymphocytic leukemia
phase ii trial for combination treatment of peg-tα1 and adefovir for hbeag positive chronic hepatitis b

Conditions: Hepatitis B, Chronic

Summary: this trial is to assess the efficacy and safety of polyethylene glycol thymosin alpha1 (peg-tα1), a new long immunomodulator (category 1.1 of chemical drugs) being developed from hansoh pharmaceutical of china, in combination with adefovir in hbeag-positive patients with chronic hepatitis b.

a total of 116 hbeag-positive patients were recruited from 12 hospitals in china, and randomized to two groups. the combination group (n= 57) received peg-tα1 (1.6 mg/ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 24 weeks. the control group (n = 59) received placebo and adefovir. both groups received adefovir continuously for additional 24 weeks. the primary endpoint was the loss of hbeag at 48 weeks. the secondary endpoints included 1) loss of hepatitis b virus ( hbv) dna, 2) hbeag seroconversion and 3) alanine aminotransferase (alt) normalization etc. at week 4, 12, 24, 36 and 48. the number of cd4＋and cd8＋t cells was also determined during 48 weeks.

Eligibility criteria:
inclusion criteria: * chronic hepatitis b for more than 6 months * alt \> 2 × upper limit normal (uln) * serum bilirubin \< 2 × uln. * positive hbeag and hbv-dna between 1.00e＋05 iu/ml and 9.99e＋09 iu/ml. * informed consent form (icf) signed. exclusion criteria: * hepatitis a,c,d,e or hiv infection. * autoimmune hepatitis. * hepatic cirrhosis. * serum creatinine \> 1.5 × uln or ccr \ uln＋3 seconds, cholinesterase\<2500u/l. * hepatitic carcinoma or alpha fetal protein (afp) \> 100ng/ml * patients with other severe diseases combined, which could affect the therapy. * patients accepted other clinical trial within 6 months before the first administrated. * patients accepted immunomodulating or anti-viral treatment within 6 months before the trial. * patients with autoimmune disease. * thymosin allergy. * pregnant or breast feeding.

Keywords: polyethylene glycol thymosin alpha1 adefovir hepatitis b e antigens positive
ultrasound assessment of the anatomic landmarks for spinal anesthesia in patients with hip fracture

Conditions: Hip Fractures

Summary: investigators assess the anatomic landmarks for spinal anesthesia in patients with hip fracture using ultrasonography.

investigators evaluate the anatomic landmarks using tuffier's line and the tenth rib line for spinal anesthesia in patients with hip fracture, and then assess the consistency of the landmarks-guided interspinous levels with the actual interspinous level using ultrasonography.

Eligibility criteria:
inclusion criteria: * patients scheduled for hip fracture surgery under spinal anesthesia exclusion criteria: * anatomic abnormalities or masses in the spine * history of spinal surgery of compression fracture
prolonging remission in depressed elderly (pride)

Conditions: Depression

Summary: this study will determine whether medications alone or medications and electroconvulsive therapy (ect) work best to prevent depressive relapse and to improve quality of life for older people with severe mood disorders.

while advances have been made in the acute treatment of geriatric depression, failure to maintain remission following successful treatment remains a major public health problem. in particular, loss of antidepressant response can result in ongoing functional impairment and increased risk of suicide. this is especially salient for severe and/or treatment resistant illness, even after successful ect. this trial builds upon the work of the consortium for research in electroconvulsive therapy (core) group that showed that continuation ect and combination pharmacotherapy were equally effective in preventing relapse following response to acute ect. we are now testing whether combined pharmacotherapy and ect, individualized according to patient response, will be more effective in maintaining remission in depressed older adults than pharmacotherapy alone. moving beyond the traditional fixed schedule for continuation ect, we are introducing a novel symptom-titrated algorithm-based longitudinal ect (stable) regimen. the stable algorithm ensures that the timing of ect treatments is based upon clinical need, helping to achieve the dual goals of adequately treating people showing early signs of symptom re-emergence, while preventing the over-treatment of patients who may be in a stable remission. the continuation therapy "usual care" comparator arm is the combination pharmacotherapy of li plus vlf (pharm). at 7 sites, 322 patients will receive an acute course of right unilateral (rul) ect augmented by standardized medication (phase i); 188 remitters are randomly assigned to one of the 2 groups and followed for 6 months (phase ii). to balance the amount of clinical contact, the schedule of clinic and telephone ratings will be identical for patients in both the pharm and stable arms. for both groups, relapse is defined as hamilton rating scale for depression-24 (hrsd24) scores \>21 at two consecutive time points, suicidality, or psychiatric hospitalization.

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of major depressive episode, unipolar, based on the mini-international neuropsychiatric interview (m.i.n.i) for dsm-iv * ect is clinically indicated exclusion criteria: * lifetime history of bipolar affective disorder, schizophrenia, schizoaffective disorder, or mental retardation * current diagnosis of delirium, dementia, or substance abuse/dependence in past 6 months as defined by dsm-iv-tr criteria

Keywords: depression ect electroconvulsive therapy mood disorders continuation ect continuation pharmacotherapy geriatric elderly lithium venlafaxine